Publications by authors named "H Peperstraete"
A randomized embedded multifactorial adaptive platform for extra corporeal membrane oxygenation (REMAP ECMO) - design and rationale of the left ventricular unloading trial domain.
Am Heart J
January 2025
Article Synopsis
- ECMO (Extracorporeal Membrane Oxygenation) has high complication rates, prompting the need for improved management strategies, which led to the development of the REMAP ECMO platform to investigate effective patient management techniques.* -
- The REMAP ECMO platform allows for multiple adaptive randomized controlled trials, with the first focusing on the effects of early left ventricular unloading via intra-aortic balloon pumping compared to ECMO alone for cardiogenic shock patients in the ICU.* -
- The primary outcome aims to determine successful weaning from ECMO at 30 days, while secondary outcomes include intervention needs, survival rates, and quality of life, all analyzed using a flexible Bayesian statistical framework.*
Article Synopsis
- Ticagrelor can be effectively given through a nasogastric tube for patients with acute coronary syndrome (ACS) when they can't take it orally, and it was tested for its effects on platelet inhibition in resuscitated patients and those needing semi-urgent CABG surgery.
- In the study, crushed ticagrelor tablets resulted in significant platelet inhibition, with 89% of resuscitated patients and 85% of CABG patients showing effective results at 24 hours.
- The pharmacokinetics revealed a median time to peak plasma concentration of 100 hours for ticagrelor across both patient groups, indicating that crushed administration maintains its effectiveness and absorption metrics similar to previous research.
Background: Randomized, controlled trials have shown both benefit and harm from tight blood-glucose control in patients in the intensive care unit (ICU). Variation in the use of early parenteral nutrition and in insulin-induced severe hypoglycemia might explain this inconsistency.
Methods: We randomly assigned patients, on ICU admission, to liberal glucose control (insulin initiated only when the blood-glucose level was >215 mg per deciliter [>11.
COVID-19 is associated with an increased risk for thrombotic complications. The trials investigating the optimal thromboprophylactic dose are performed in challenging times and seemingly produce conflicting evidence. The burdensome circumstances, divergent endpoints, and different analytical approaches hamper comparison and extrapolation of available evidence.
View Article and Find Full Text PDFPotential of Urine Biomarkers CHI3L1, NGAL, TIMP-2, IGFBP7, and Combinations as Complementary Diagnostic Tools for Acute Kidney Injury after Pediatric Cardiac Surgery: A Prospective Cohort Study.
Diagnostics (Basel)
March 2023
Acute kidney injury (AKI) is common after pediatric cardiac surgery (CS). Several urine biomarkers have been validated to detect AKI earlier. The objective of this study was to evaluate urine CHI3L1, NGAL, TIMP-2, IGFBP7, and NephroCheck as predictors for AKI ≥ 1 in pediatric CS after 48 h and AKI ≥ 2 after 12 h.
View Article and Find Full Text PDF